All episodes

In rare cases, coronavirus vaccines may cause Long Covid–like symptoms

Two full years after the pandemic began, it is now time to consider our next moves. In order to maintain a clear overview, Salvagene placed great emphasis on accurate documentation and ongoing information exchange right from the start. This meticulous approach, together with insights from science and research findings, enabled us to make precisely tailored recommendations for our clients. In the last few weeks and months, we have been gathering up loose ends and shifting our focus to appropriate preventive measures as well as preparations for the aftermath of the Covid-19 pandemic.

According to the latest figures, between 10 and 30 percent of all persons who test positive for SARS-CoV-2 go on to develop long-term symptoms that can last for weeks, months or potentially even years.
These can vary greatly depending on the severity of the disease, the age of the patient and his or her medical history. When – or indeed whether – those who suffer so‑called “Long Covid” can expect their symptoms to clear up is unclear, and there is as is as yet no treatment for the condition that does more than just alleviate symptoms.
A U.S.-based research group...

Paxlovid received emergency approval in the USA just before Christmas, and it may get the all-clear for use in Europe as early as January. This new medication could help reduce the number of people who fall severely ill with COVID-19, but supply shortages and manufacturing problems are so far hindering widespread distribution.

Taken early enough after a diagnosis of COVID-19, paxlovid could dramatically reduce the risk of severe illness. Its manufacturer, Pfizer, claims that the likelihood of hospitalization or death for high-risk patients following an infection is reduced by almost 90 percent. Many in the medical profession are now hoping...

We look at the strategies employed by viruses against this tumor suppressor gene.

Since the onset of the pandemic, research has been conducted into the extent to which SARS-Cov-2 affects the p53 tumor suppressor gene and its pathway. Two widely published studies from 2020 and 2021 have provided interesting insights into this, revealing the molecular strategies by means of which viruses such as SARS-CoV-2 target the p53 function.
It is also interesting to compare the combat strategies of other viruses with those of SARS-CoV-2, and we will also briefly discuss this below.

The number of infections worldwide is on the increase, and with it, the number of vaccine breakthroughs. However, it is not only the rising rate of infection that is the root cause of this, but also the waning effect of the vaccines themselves. Nevertheless, individuals without any form of immunization are significantly less protected against COVID‑19 disease, and the mRNA booster jabs seem to be delivering on their promise of offering almost complete protection. There are multiple factors at play here that will continue to occupy our attention this winter. In the meantime, this is how we see the current...

What you need to know about the influenza season in general and high-dose vaccines in particular.
Social distancing, face coverings and strict hygiene controls not only reduced the spread of SARS-CoV-2 last year but also of influenza viruses. Flu activity is currently still at a low level, but nonetheless slightly higher than at this time in previous years. Researchers and authorities in the USA and Europe are predicting that a particularly virulent wave of influenza will hit the northern hemisphere in the winter months of 2021/22 and are therefore advising senior citizens to get a shot of the relatively new...

Current status and news of new concepts such as antibody therapy and vaccination by inhalation against COVID-19 infection.

We at Dr Robert Hess's Task Force have a special interest in this topic, because for some of our premium members the conventional vaccination against Covid-19 is not an option or even can be counterproductive. We see these new concepts as possible solutions for additional protection against coronavirus infection without the need for vaccination.
In certain cases, monoclonal antibodies (MAK) are considered to be a promising drug against severe disease progression in SARS-CoV-2 infection and have been used in the clinical setting...

What exactly does full FDA approval of a vaccine mean?
The Pfizer/BioNTech COVID-19 vaccine first received Emergency Use Authorization (EUA) from the U.S. authorities in mid-December 2020 for administration to persons aged 16 and older. On Monday, the FDA announced that it has now granted full approval. The vaccine has thus become the first to receive FDA approval for use against coronavirus. More are expected to follow in the coming weeks and months.
Emergency Use Authorization continues to apply for use on adolescents aged 12 to 15 years and for administration as a third booster dose to immunocompromised individuals.
Further...

Any decision on whether to receive a booster jab (and which one to choose) or to wait for a next-generation vaccine should be based on the following criteria.